explore -WSS

explore

author：Wikipedia 2025-08-27 22:46:20 - browse：8

This is the inaugural edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

Hello! Welcome to the premiere issue of Adam’s Biotech Scorecard. I’m excited to get started. Let’s do this! (By the way, the AF in the logo are my initials, not the “other” AF.)

The contrarian view of Viking Therapeutics

Closeup financial chart

The developer of a dual-acting GLP-1/GIP treatment for obesity is riding high on positive data and takeout speculation. The drug, called VK2735, has shown impressive weight loss with minimal gastrointestinal side effects in both subcutaneous and oral formulations, positioning it as a strong challenger to the obesity juggernauts from Eli Lilly and Novo Nordisk. With a stock price that has soared nearly 800% over the past year, Viking is now a $9 billion company and a prime acquisition target for a cash-rich pharma company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Digital health funding stays low as a new reality sets in

WSS

The debate over Covid

Acelyrin, a rare IPO success, stumbles in its first big test

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

WATCH: Why do bright lights make us see spots?

Vermont grapples with historic flooding as more rainstorms head for Northeast

Giant panda gives birth to squirming, squealing healthy twin girls at South Korean theme park

Wikipedia

explore

The contrarian view of Viking Therapeutics

explore

How to save PrEP access — and even expand it

Grail's uphill battle for Medicare to cover its cancer screening test

In Memoriam: Notable people who died in 2023

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Jerome Adams on the need for new antivirals for Covid

Walmart eyes Medicare Advantage provider ChenMed

Novavax promises a turnaround & Lilly roils the obesity market

Generate Biomedicines machine learning biotech raises $273M

Medical records are filled with copy

Superbugs, antibiotic resistance get scrutiny in congress

explore

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

Rapinoe says her retirement call will help US women's soccer team to focus at World Cup

Generate Biomedicines machine learning biotech raises $273M

Blinken talks high

The debate over Covid

Acelyrin, a rare IPO success, stumbles in its first big test

Wikipedia

focus

focus

Wikipedia